Compare LINC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | TBPH |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.7M | 908.9M |
| IPO Year | 2005 | 2013 |
| Metric | LINC | TBPH |
|---|---|---|
| Price | $25.64 | $17.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $45.00 | $18.40 |
| AVG Volume (30 Days) | ★ 1.3M | 390.5K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 279.13 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $261,853,000.00 | $15,386,000.00 |
| Revenue This Year | $15.16 | $8.46 |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | $128.78 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $17.29 | $13.08 |
| 52 Week High | $56.34 | $21.03 |
| Indicator | LINC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 65.18 |
| Support Level | $25.27 | $16.80 |
| Resistance Level | $28.00 | $17.11 |
| Average True Range (ATR) | 1.50 | 0.05 |
| MACD | 0.43 | 0.01 |
| Stochastic Oscillator | 27.67 | 89.19 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.